Whalesbook
New Nutritional Support Launched
The joint venture between Dr. Reddy's Laboratories and Nestlé Health Science has launched Celevida GLP+ in India. This specialized nutritional supplement is designed for patients undergoing GLP-1/GIP therapies for type 2 diabetes and obesity. It aims to help manage common side effects and support patient well-being during these treatments.
Product Details and Market Timing
Launched on May 7, 2026, Celevida GLP+ targets critical nutritional gaps for patients on GLP-1/GIP therapy. It offers 48 grams of protein per 100 grams, 100% Recommended Dietary Allowance (RDA) of branched-chain amino acids (BCAAs), and 27 essential nutrients, including vitamins A and D, and calcium. The timing is strategic, coinciding with the March 20, 2026, patent expiry of semaglutide in India, a move expected to boost generic availability and patient access. Dr. Reddy’s stock (REDY) is trading around ₹1,306.10 INR with a market cap of ₹1.09 trillion INR. Its 52-week range is ₹1,138.50 to ₹1,379.70 INR, and its P/E ratio is approximately 17-19x. This launch aims to capture part of India's GLP-1 market, projected to reach $1 billion by fiscal 2030.
Market Landscape and Competition
The Indian nutritional supplements market is growing rapidly, forecast to reach INR 572.62 billion by 2034. Celevida GLP+ enters a competitive field with established players like Abbott India, Dabur, and Sun Pharmaceutical Industries already active in vitamins, minerals, and protein supplements. Nestlé Health Science also offers relevant products like Resource High Protein and Resource Diabetic in India. While specific competitors for GLP-1 support supplements are new, the broader market for diabetes and obesity nutrition is significant. The Indian GLP-1 receptor agonist market was valued at about USD 110.55 million in 2024 and is projected to grow at a 34.3% CAGR, fueled by wider generic availability. Analysts typically offer mixed to positive views on Dr. Reddy's, often rating the stock 'Hold' or 'Neutral' with price targets indicating potential upside. The company's P/E ratio is currently below the market average.
Potential Challenges Ahead
However, the product's success depends on widespread patient adherence to GLP-1/GIP therapies. The sharp price drops in generic GLP-1 drugs, while improving access, also increase competition and could lower treatment costs, potentially impacting the value of add-on products like Celevida GLP+. Dr. Reddy's faces competition from other specialized nutrition brands and the increasing awareness that proper protein intake and exercise are key to preventing muscle loss during GLP-1 therapy. The company has also encountered patent disputes, including a court order that temporarily barred Dr. Reddy's and OneSource Specialty Pharma from marketing Semaglutide active ingredient in India, indicating potential regulatory and IP challenges in the GLP-1 sector. Competition in the niche GLP-1 support supplement market is expected to be intense from both existing companies and new entrants capitalizing on generic drug availability.
Analyst Views and Growth Prospects
Analysts have set a consensus price target for Dr. Reddy's Laboratories (REDY) around $16.90, suggesting a potential 25.5% upside from its current price. Growth is expected to be driven by diversified revenue streams, including its expanding consumer healthcare unit and specialized products like Celevida GLP+. Integrated patient support solutions are viewed by analysts as key to improving long-term patient outcomes and building recurring revenue, which could boost valuation as the specialized nutrition sector develops. For fiscal year 2025, the company reported INR 325.54 billion in revenue, up 16.61% from the prior year.